SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Whitley P)
 

Search: WFRF:(Whitley P) > Herpes Simplex Ence...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006627naa a2201021 4500
001oai:gup.ub.gu.se/224039
003SwePub
008240528s2015 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:d9f62c58-30db-4749-b398-65f298f3f0bf
009oai:DiVA.org:umu-109931
009oai:prod.swepub.kib.ki.se:131998807
009oai:DiVA.org:uu-255858
0247 a https://gup.ub.gu.se/publication/2240392 URI
0247 a https://doi.org/10.1093/cid/civ3692 DOI
0247 a https://lup.lub.lu.se/record/54536822 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1099312 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1319988072 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2558582 URI
040 a (SwePub)gud (SwePub)lud (SwePub)umud (SwePub)kid (SwePub)uu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Gnann, J. W.4 aut
2451 0a Herpes Simplex Encephalitis: Lack of Clinical Benefit of Long-term Valacyclovir Therapy
264 c 2015-05-08
264 1b Oxford University Press (OUP),c 2015
520 a Background. Despite the proven efficacy of acyclovir (ACV) therapy, herpes simplex encephalitis (HSE) continues to cause substantial morbidity and mortality. Among patients with HSE treated with ACV, the mortality rate is approximately 14%-19%. Among survivors, 45%-60% have neuropsychological sequelae at 1 year. Thus, improving therapeutic approaches to HSE remains a high priority. Methods. Following completion of a standard course of intravenous ACV, 87 adult patients with HSE (confirmed by positive polymerase chain reaction [PCR] for herpes simplex virus DNA in cerebrospinal fluid) were randomized to receive either valacyclovir (VACV) 2 g thrice daily (n = 40) or placebo tablets (n = 47) for 90 days (12 tablets of study medication daily). The primary endpoint was survival with no or mild neuropsychological impairment at 12 months, as measured by the Mattis Dementia Rating Scale (MDRS). Logistic regression was utilized to assess factors related to the primary endpoint. Results. The demographic characteristics of the 2 randomization groups were statistically similar with no significant differences in age, sex, or race. At 12 months, there was no significant difference in the MDRS scoring for VACV-treated vs placebo recipients, with 85.7% and 90.2%, respectively, of patients demonstrating no or mild neuropsychological impairment (P = .72). No significant study-related adverse events were encountered in either treatment group. Conclusions. Following standard treatment with intravenous ACV for PCR-confirmed HSE, an additional 3-month course of oral VACV therapy did not provide added benefit as measured by neuropsychological testing 12 months later in a population of relatively high-functioning survivors.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Mikrobiologi inom det medicinska området0 (SwePub)301092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Microbiology in the medical area0 (SwePub)301092 hsv//eng
653 a herpes simplex virus
653 a encephalitis
653 a antiviral therapy
653 a valacyclovir
653 a acyclovir
653 a polymerase-chain-reaction
653 a central-nervous-system
653 a virus-encephalitis
653 a cerebrospinal-fluid
653 a adult patients
653 a combination therapy
653 a acyclovir
653 a therapy
653 a diagnosis
653 a multicenter
653 a management
653 a Immunology
653 a Infectious Diseases
653 a Microbiology
653 a herpes simplex virus
7001 a Skoldenberg, B.4 aut
7001 a Hart, J.4 aut
7001 a Aurelius, E.u Karolinska Institutet4 aut
7001 a Schliamser, Silviau Lund University,Lunds universitet,Infektionsmedicin,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Infection Medicine (BMC),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)infek-ss
7001 a Studahl, Marie,d 1957u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xstuma
7001 a Eriksson, Britt-Marieu Uppsala universitet,Infektionssjukdomar4 aut0 (Swepub:uu)breri424
7001 a Hanley, D.4 aut
7001 a Aoki, F.4 aut
7001 a Ahlm, Clasu Umeå universitet,Institutionen för klinisk mikrobiologi4 aut0 (Swepub:umu)clah0001
7001 a Griffiths, P.4 aut
7001 a Miedzinski, L.4 aut
7001 a Hanfelt-Goade, D.4 aut
7001 a Hinthorn, D.4 aut
7001 a Ahlm, C.4 aut
7001 a Aksamit, A.4 aut
7001 a Cruz-Flores, S.4 aut
7001 a Dale, I.4 aut
7001 a Cloud, G.4 aut
7001 a Jester, P.4 aut
7001 a Whitley, R. J.4 aut
7001 a Jackson, Alan C4 aut
7102 a Karolinska Institutetb Infektionsmedicin4 org
7730 t Clinical Infectious Diseasesd : Oxford University Press (OUP)g 61:5, s. 683-691q 61:5<683-691x 1058-4838x 1537-6591
8564 u https://academic.oup.com/cid/article-pdf/61/5/683/862192/civ369.pdf
8564 u http://www.ncbi.nlm.nih.gov/pubmed/25956891?dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1093/cid/civ369y FULLTEXT
8564 8u https://gup.ub.gu.se/publication/224039
8564 8u https://doi.org/10.1093/cid/civ369
8564 8u https://lup.lub.lu.se/record/5453682
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-109931
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:131998807
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-255858

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view